Recombinant Humanized Monoclonal Antibody MIL62 Injection

DRUG4 trials

Sponsors

Beijing Mabworks Biotech Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd.

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryCD20-positive B Cell Non-Hodgkin LymphomaFollicular Lymphoma and Marginal Zone LymphomaLupus Nephritis

Phase 1

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

CompletedNCT04103905

Beijing Mabworks Biotech Co., Ltd.CD20-positive B Cell Non-Hodgkin Lymphoma

Start: 2017-02-10End: 2020-05-29Updated: 2025-05-18

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

RecruitingNCT04110301

Beijing Mabworks Biotech Co., Ltd.Follicular Lymphoma and Marginal Zone Lymphoma

Start: 2019-11-28End: 2025-05-31Target: 53Updated: 2024-11-20

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Active, not recruitingNCT04304040

Beijing InnoCare Pharma Tech Co., Ltd.B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory

Start: 2020-07-28End: 2025-12-30Updated: 2024-02-07

Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

Active, not recruitingNCT07044115

Beijing Mabworks Biotech Co., Ltd.Lupus Nephritis

Start: 2021-11-26End: 2025-08-31Updated: 2025-07-02

Related Papers

Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial.

2024-06-201 citations

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Blood2021-11-051 citations